IMUX (Immunic) Tariff Resilience Score: 6/10 (As of Jun. 28, 2026)


IMUX Immunic Inc IMUX
32 GF Score
Price $15.15
! 3 Warning Signs
View Full Analysis

What is Immunic Tariff Resilience Score?

Immunic IMUX +1.53% 32 Tariff Resilience Score is 6 as of Jun. 28, 2026. GuruFocus rates IMUX with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,378 Biotechnology companies, Immunic ranks better than 75.98% on this metric.

Immunic has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Immunic has Immunic Inc, focused on drug development, has moderate tariff exposure. Its operations are primarily in the U.S. and Europe, with limited reliance on imported materials. The company has some pricing power in its niche market.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Immunic might have Average Resilient.

Immunic  (NAS:IMUX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Immunic Tariff Resilience Score Related Terms

IMUX vs KPTI, INDP, UNCY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Immunic's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunic Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunic's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Immunic's Tariff Resilience Score falls into.


IMUX
32GF Score
Immunic Inc IMUX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Immunic (IMUX) has a Tariff Resilience Score of 6 as of Jun. 28, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Immunic ranks #331 out of 1378 companies in the Biotechnology industry, placing it in the top 24%.
Is Immunic's Tariff Resilience Score too high?
Immunic's current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Immunic's value of 6 is 50% above this industry median. Based on the distribution chart, Immunic ranks #331 out of 1378 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Immunic has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Immunic's Tariff Resilience Score compare to KPTI and INDP?
According to the Biotechnology industry distribution chart, Immunic ranks #331 out of 1378 companies for Tariff Resilience Score. This places Immunic in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Immunic's value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,378 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immunic's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immunic's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunic stock overvalued right now?
Immunic (IMUX) has a current Tariff Resilience Score of 6. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Immunic's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Immunic (IMUX), the current Tariff Resilience Score is 6 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immunic Business Description

Other Exchanges 10V:Germany
Address 1200 Avenue of the Americas, Suite 200, New York, NY, USA, 10036
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
32GF Score

Get the complete analysis for IMUX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.15
Price